



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANTS

(use as many sheets as necessary)

Sheet

of

Complete if Known	
Application Number	10/824,731
Filing Date	April 15, 2004
First Named Inventor	James Patrick Dunn
Art Unit	T014 1626
Examiner Name	Not yet assigned G. Shameem
Attorney Docket Number	R0163B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
GS	C1	WO 92/07844 A1	14-May-1992	Pfizer Inc., Groton, CT		
GS	C2	EP 1 052 254 A1	15-Nov-2000	Eisai Co., Ltd. Tokyo, JP		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GS	C3	WANDEL, et al, "P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies ¹ ", Cancer Research , August 15, 1999, pp 3944-3948, Vol 59:16	
GS	C4	WEBB, et al., "Quinazolines as Adenosine Receptor Antagonists: SAR and Selectivity for A _{2B} Receptors", Bioorganic & Medicinal Chemistry , (2003), pp 77-85, Vol 11	
GS	C5	HESS, et al., "Antihypertensive 2-Amino-4(3H)-quinazolines", Journal of Medicinal Chemistry , (1968), pp 130-136, Vol 11:1	

Examiner Signature	/Golam Shameem/ (06/29/2006)	Date Considered	06/29/2006
--------------------	------------------------------	-----------------	------------

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Doc. #128569

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Attorney Docket Number

Application Number

10/824,731

Filing Date

April 15, 2004

First Named Inventor

James Patrick Dunn

Art Unit

1614 1626

Examiner Name

Not yet assigned

Sheet

of

Attorney Docket Number

R0163B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Passages, Figures
		Number - Kind Code ² (if known)			
GS	B1	US-6,476,031	11-05-2002	Scios, Inc.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
GS	B2	GB 1,024,908	04-06-1966	Monsanto Chemicals Limited		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GS	B3	SHEWCHUK, L., et al, "Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase", J. Med. Chem, 2000, 43:133-138 (XP002293111, compounds 1-3)	

Examiner Signature	/Golam Shameem/ (06/29/2006 Considered	06/29/2006
--------------------	---	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. #128444V1